CL-197 vs Emtricitabine (Emtriva)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

CL-197

Developed by Henan Genuine Biotech

Phase 2 in HIVsmall molecule
Weak signal

NCT05944848 · Phase 1 · completed

The study randomly assigned healthy volunteers to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, it tested only safety and drug levels in healthy volunteers rather than any HIV outcome, and results have not been posted. Its registered primary outcome on ClinicalTrials.gov is "The Safety and Tolerability of CL-197 Capsules :Incidence of Treatment-Emergent Adverse Events as Assessed by The NCI CTCAE V5.0 Grading Criteria". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07308782 (registry estimate)

No aligned efficacy figure on record for this race.

Emtricitabine (Emtriva)

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT00112047 · Phase 3 · completed

The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.

Next expected readout: June 2029 · NCT07792096 (registry estimate)

Reported efficacy

Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)

Result source: NCT00112047

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCL-197Emtricitabine (Emtriva)
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not posted · NCT00002416
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not posted · NCT00002416
CD4 count, change (week 48)—Not reported—Not posted · NCT00002416

HIV-1 RNA below 50 copies/mL (week 48)

CL-197
—Not reported
Emtricitabine (Emtriva)
—Not posted · NCT00002416

HIV-1 RNA 50 copies/mL or more (week 48)

CL-197
—Not reported
Emtricitabine (Emtriva)
—Not posted · NCT00002416

CD4 count, change (week 48)

CL-197
—Not reported
Emtricitabine (Emtriva)
—Not posted · NCT00002416
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CL-197: no structured comparison results are available for HIV.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Emtricitabine (Emtriva)
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants NCT00112047 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CL-197's landscape · Emtricitabine (Emtriva)'s landscape